Orphan drugs are registered through a specialized process managed by the Ministry of Food and Drug Safety (MFDS) in South Korea. They receive expedited review, reduced clinical trial requirements, and financial incentives. These measures encourage the development and approval of treatments for rare diseases with limited market potential.